Thirty Years of HIV and AIDS: Future Challenges and Opportunities

December 30, 2011 at 6:30 pm Leave a comment

Ann Int Med  07 June May 2011 V,154 N.11 P.766-771

Carl W. Dieffenbach and Anthony S. Fauci

From the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.

Abstract

As the third decade since AIDS was first recognized comes to an end, extraordinary advances have occurred in the understanding, treatment, and prevention of HIV infection and AIDS. As a result of these successes, it is now time to focus on future challenges.Paramountamong these is reaching the goal of truly controlling and ultimately ending the HIV and AIDS pandemic.

To that end, AIDS researchers and public health personnel worldwide are aggressively pursuing 3 key areas of scientific research. Given the availability of highly effective therapeutic regimens for HIV infection, the first challenge is efficiently identifying a maximum number of HIV-infected persons through voluntary HIV testing and initiating antiretroviral therapy (ART). Second, scientists are trying to develop a cure for HIV infection, which would alleviate the need for lifelong ART. Finally, preventing new cases of HIV infection, which currently number approximately 2.6 million per year globally, is critical to any attempt to end this pandemic. This article addresses each of these challenges and provides directions for the future.

Abstract

http://www.annals.org/content/early/2011/05/27/0003-4819-154-11-201106070-00345.abstract?papetoc

PDF

http://www.annals.org/content/early/2011/05/27/0003-4819-154-11-201106070-00345.full.pdf+html

Entry filed under: Antirretrovirales, Biología Molecular, Epidemiología, HIV/SDA en Seniles, HIV/SIDA, HIV/SIDA HAART, HIV/SIDA Infeccion Aguda / Reciente, HIV/SIDA Infecciones Oportunistas, HIV/SIDA Laboratorio, HIV/SIDA Mujeres, HIV/SIDA Prevencion.

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV Type-1: A Randomized Trial

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Calendar

December 2011
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Most Recent Posts


%d bloggers like this: